Guided TE vs Blind VCTE: Why Visibility Changes Everything
iLivTouch and FibroScan both use transient elastography — the gold-standard technology for liver stiffness measurement. The difference is guidance. iLivTouch adds real-time B-mode imaging so the operator can see exactly where they are measuring. Blind VCTE cannot.
The Physics: Same Technology, Different Execution
Both iLivTouch and FibroScan use transient elastography (TE). A mechanical vibration from the probe tip generates a shear wave through liver tissue. The velocity of that wave is measured and converted to liver stiffness in kPa using the elastic modulus equation:
E = 3ρV² (where E = elastic modulus in kPa, ρ = tissue density, V = shear wave velocity)
Both devices produce liver stiffness in kPa, are referenced in EASL, AASLD, and GESA guidelines, and have comparable diagnostic accuracy for detecting significant fibrosis (≥F2) and cirrhosis (≥F4) across published literature.
The critical operational difference is not the wave technology. It is that iLivTouch provides real-time B-mode imaging simultaneously, enabling the operator to visualise the liver parenchyma, identify and avoid major vessels, and confirm measurement location before accepting results. Standard FibroScan models acquire measurements without this visual confirmation — the operator cannot see the liver during acquisition.
VCTE's quality output (IQR/M ratio ≤30%) confirms mathematical consistency across 10 shots. It cannot confirm that those 10 shots were placed in appropriate liver tissue. A cluster of consistent measurements taken through an undetected vessel or in the wrong anatomical plane will still pass the IQR/M test. Visual guidance eliminates this ambiguity.
Comparative Performance: Guided vs Blind
| Parameter | FibroScan (Blind VCTE) | iLivTouch (Guided TE) |
|---|---|---|
| Wave technology | Transient Elastography (TE) | Transient Elastography (TE) |
| Guidance during acquisition | None — blind probe positioning | Real-time B-mode ultrasound imaging |
| Overall CLD success rate | ~88.4% | ~94.8% |
| Failure rate in CLD | ~11.6% | ~5.16% |
| Rescue rate of VCTE failures | N/A (device abandoned) | 61% of blind VCTE failures completed |
| BMI >30 performance | M probe: ~75–80% success; XL probe required separately | Significantly lower failure with real-time guidance |
| Quality validation | IQR/M ratio ≤30% (mathematical, not visual) | Visual B-mode confirmation + IQR/M ratio |
| Ascites patients | Unreliable — signal attenuation | Visual identification and avoidance possible |
| Operator dependency | High — blind probe positioning | Lower — operator can see what they are measuring |
Failure rate and rescue data from comparative chronic liver disease studies. Find references via PubMed: search PubMed for guided vs blind elastography failure rate studies
What the 61% Rescue Rate Means Clinically
For every 100 patients sent for liver fibrosis assessment, approximately 11–12 will return an incomplete result from blind VCTE. Of those, guided TE will provide a valid result in roughly 7–8 cases. The remaining 3–4 require clinical judgement without a stiffness measurement.
For a high-BMI MASLD population — Australia's most prevalent liver disease demographic — this differential is more pronounced. Guided TE's real-time imaging addresses the root cause of blind VCTE failure (inability to confirm probe placement) rather than mitigating it through probe substitution. The FibroScan XL probe reduces M-probe failure in high-BMI patients, but still acquires measurements without visual confirmation.
Diagnostic Accuracy: AUROC Comparison
Both guided and blind TE achieve comparable AUROC values for detecting significant fibrosis (≥F2) and advanced fibrosis/cirrhosis (≥F3–F4) in published literature, with variability by disease aetiology and cohort composition. The relevant discriminator for most clinical decisions is success rate and confidence of measurement placement, not AUROC alone.
Where guided TE demonstrates a consistent advantage in comparative studies:
- Reducing failed examinations across all patient types, particularly high BMI
- Visual confirmation that measurements were taken from appropriate liver parenchyma
- Enabling assessment of patients blind VCTE cannot complete
- Lower operator dependency — a less-experienced operator can confirm correct positioning
The MSAC 1797 Context
In early 2025, MSAC declined to fund standalone VCTE (FibroScan) on the Australian MBS for MASLD assessment, concluding that FIB-4 already performs the rule-out function at near-zero cost. Guided elastography performed alongside abdominal ultrasound can attract a partial Medicare rebate of approximately $100–$120 under existing item numbers — a pathway not available to standalone VCTE devices.
This regulatory difference has immediate commercial implications for practices making capital allocation decisions. Read the full MSAC 1797 analysis →
Frequently Asked Questions
What is the failure rate of FibroScan (blind VCTE) compared to guided elastography?
In chronic liver disease populations, blind VCTE (FibroScan) has an overall failure rate of approximately 11.6% compared to approximately 5.16% for guided elastography systems. In cases where blind VCTE returned no valid result, a guided system provided a valid measurement in approximately 61% of those patients. The driver of this difference is visual guidance — not the wave technology itself.
Do iLivTouch and FibroScan use the same elastography technology?
Yes. Both iLivTouch and FibroScan use transient elastography (TE): a mechanical vibration generates a shear wave in liver tissue, and wave velocity is converted to liver stiffness in kPa. The critical difference is that iLivTouch integrates real-time B-mode ultrasound imaging so the operator can see exactly where measurements are being taken. Standard FibroScan models acquire measurements blind — without visual confirmation of probe placement.
Why does blind VCTE fail more often in obese patients?
Blind VCTE uses a probe without real-time B-mode imaging — the operator cannot see the liver during acquisition and cannot confirm probe placement or avoid vessels. In patients with high BMI, the M probe failure rate rises to 20–25%. The XL probe partially mitigates this, but cannot address the fundamental limitation of acquiring measurements without visual confirmation. Guided TE allows the operator to identify optimal liver parenchyma before acquisition, significantly reducing failure regardless of patient body habitus.
What does the 61% rescue rate mean clinically?
For every 100 patients sent for liver fibrosis assessment, approximately 11–12 will return an incomplete result from blind VCTE. Of those, a guided system will provide a valid result in roughly 7–8 cases. In a high-BMI MASLD population — Australia's most prevalent liver disease demographic — this differential is more pronounced. The rescue rate means guided systems deliver a clinically actionable result for the majority of patients who would otherwise leave a blind VCTE examination without a usable reading.
See guided TE in your clinical context
Request a demonstration to compare iLivTouch's guided TE workflow against your current blind VCTE setup.
Request clinical demonstration